Initial Workup and Diagnostic Approach for Suspected Neuroendocrine Tumors

Immediate Referral

• Refer all patients with suspected neuroendocrine tumors to specialized multidisciplinary centers before initiating definitive workup. 1, 2, 3

Histological Confirmation

• Obtain tissue via endoscopic biopsy, surgical resection, or ultrasound‑guided core needle biopsy from the primary lesion or metastatic sites (especially liver) for every suspected case. 4, 1, 5
• Perform immunohistochemical staining for chromogranin A and synaptophysin, which are positive in 90‑100 % of neuroendocrine tumors. 1, 2
• Determine the Ki‑67 proliferation index (MIB‑1) in all specimens; it is mandatory for WHO 2010 grading. 4, 1, 2
• Classify tumors according to WHO 2010 Ki‑67 criteria: G1 ≤ 2 %, G2 3‑20 %, G3 > 20 %. 4, 1
• Hormone‑specific staining (e.g., serotonin, gastrin, insulin) can identify the source of symptoms but does not prove functional secretion; correlate with biochemical tests. 4, 1, 2

Baseline Biochemical Testing

• Measure plasma chromogranin A in all patients; sensitivity is 60‑80 % for well‑differentiated NETs, but it is often normal in poorly differentiated G3 tumors, where neuron‑specific enolase may be used instead. 4, 3, 1
• Perform a 24‑hour urinary 5‑hydroxyindoleacetic acid (5‑HIAA) test; it is elevated in ~70 % of mid‑gut NETs and has ~90 % specificity for carcinoid syndrome. 4, 3
• Apply syndrome‑specific biochemical tests as indicated:
  
  • Urinary 5‑HIAA for carcinoid syndrome. 4, 5
  • Fasting serum gastrin for Zollinger‑Ellison syndrome. 4, 5
  • Fasting insulin, pro‑insulin and C‑peptide (with supervised fasting) for hypoglycemia. 4, 5
  • Serum glucagon for glucagonoma syndrome. 4
  • Serum VIP for VIPoma/Verner‑Morrison syndrome. 4
  • Serum pancreatic polypeptide may be elevated in non‑functioning pancreatic NETs. 4

Multimodal Imaging Strategy

• Combine functional somatostatin‑receptor imaging with anatomical CT/MRI for comprehensive staging. 4, 1, 3
• First‑line functional imaging: Gallium‑68 DOTA‑peptide PET/CT, which shows 90‑95 % sensitivity for detecting unknown primaries and for staging. 3
• If Gallium‑68 PET/CT is unavailable, use somatostatin‑receptor scintigraphy (Octreoscan) plus CT, providing 80‑90 % sensitivity. 4, 1, 3
• Perform contrast‑enhanced CT or MRI of the abdomen/pelvis for anatomical localization, liver‑metastasis assessment, and surgical planning; sensitivity 80‑90 %. MRI is preferred for pancreatic NETs due to superior soft‑tissue contrast and lack of radiation. 4, 1, 3
• Endoscopic ultrasound (EUS) detects small pancreatic and gastric NETs and enables EUS‑guided fine‑needle aspiration; reported sensitivity approaches 100 % in expert centers. 4, 1, 3
• Upper endoscopy, colonoscopy, and capsule endoscopy are useful for identifying gastric, rectal, and small‑bowel primaries. 4, 1, 3
• Advanced PET tracers (¹¹C‑5HTP, ¹⁸F‑DOPA) may improve staging when available. 4, 1
• ¹⁸F‑FDG PET is reserved for poorly differentiated G3 neuroendocrine carcinomas with high proliferative activity. 6, 5
• Because a subset of NETs lack somatostatin‑type 2 receptors, anatomical CT/MRI must always accompany receptor imaging to avoid missing receptor‑negative disease. 4, 1, 2

Genetic and Syndromic Screening

• Conduct a thorough clinical examination and family‑history assessment in every NET patient to identify hereditary syndromes. 1, 2, 3
• Suspect MEN‑1 or von Hippel‑Lindau disease when there is a family history of NETs, the presence of a second endocrine tumor (e.g., parathyroid or pituitary adenoma), or onset 15‑20 years earlier than typical sporadic NETs. 3, 4, 1, 2
• Patients with MEN‑1 or VHL frequently develop multiple pancreatic NETs and require tailored surveillance protocols. 4, 1, 2

TNM Staging

• After imaging, apply site‑specific TNM criteria:
  
  • T stage – based on tumor size, depth of invasion, and organ involvement. 4, 2
  • N stage – assessment of regional lymph‑node metastasis. 4, 2
  • M stage – detection of distant metastases, most commonly hepatic. 4, 2

Common Diagnostic Pitfalls

• Do not rely solely on hormone immunohistochemistry to infer tumor functionality; confirm with biochemical markers and clinical signs. 4, 1, 2
• Avoid using only anatomical imaging, as it may miss small primaries and receptor‑positive lesions; functional imaging is essential. 4, 3
• Failure to obtain a Ki‑67 index leads to inaccurate WHO grading and inappropriate therapeutic decisions. 4, 1

Diagnostic Algorithm (Key Steps)

Diagnostic and Treatment Approach for Pancreatic and GI Neuroendocrine Tumors

Initial Biochemical Workup

• The European Neuroendocrine Tumor Society recommends obtaining plasma chromogranin A and 24-hour urinary 5-HIAA as baseline tests for diagnosing pancreatic and GI neuroendocrine tumors, followed by histological confirmation through biopsy 7, 8
• Plasma chromogranin A serves as a general NET marker, particularly useful in gastric carcinoids with metastases, with a sensitivity of 60-80% 9, 10, 11
• 24-hour urinary 5-HIAA is essential for detecting carcinoid syndrome, raised in 70% of midgut NETs, with a specificity of 90% 9, 10, 12
• Additional general markers, such as calcium, thyroid function tests, PTH, calcitonin, prolactin, CEA, AFP, and β-HCG, should be measured to rule out other conditions 9, 10, 12
• The strength of evidence for these markers is moderate to high, based on multiple studies and guidelines 9, 10, 11, 12

Histological Confirmation

• Histopathology is mandatory in all cases and should be obtained via endoscopic biopsy, surgical specimen, or ultrasound-guided core needle biopsy from the primary or metastatic site, with a diagnostic accuracy of 90-95% 7, 11, 13
• Required immunohistochemical staining includes pan-neuroendocrine markers, such as chromogranin A and synaptophysin, which are positive in 90-100% of NETs 11
• Ki-67 proliferation index is essential for WHO grading and treatment selection, with a prognostic value of 80-90% 11, 14
• Hormone-specific staining, such as serotonin, gastrin, insulin, and glucagon, can confirm the source of symptoms but does not prove functionality, with a sensitivity of 50-70% 11

Imaging Strategy

• A multimodality approach, including Gallium-68 PET/CT, somatostatin receptor scintigraphy (SSRS) combined with CT, and contrast-enhanced CT or MRI of abdomen/pelvis, is recommended for detecting the primary tumor and staging, with a diagnostic accuracy of 90-95% 7, 8, 11
• Gallium-68 PET/CT is the most sensitive modality for detecting unknown primaries and staging, with a sensitivity of 90-95% 7, 8
• SSRS combined with CT is an alternative to Gallium-68 PET/CT, with a sensitivity of 80-90% 7, 8
• Contrast-enhanced CT or MRI of abdomen/pelvis is essential for anatomical localization and liver metastases, with a sensitivity of 80-90% 11, 14, 13

Genetic and Syndromic Evaluation

• Clinical examination and detailed family history are essential to exclude multiple endocrine neoplasia type 1 (MEN-1) and Von Hippel-Lindau disease, with a prevalence of 10-20% in NET patients 7, 8, 11, 14
• Suspect familial syndrome when family history of carcinoids/NETs exists or patient has a second endocrine tumor, with a risk of 20-30% 7, 8

Treatment Algorithm

• Surgery is the only curative treatment and first-line therapy for all resectable disease, with a 5-year survival rate of 80-90% 7, 15
• Formal pancreatectomy with lymph node sampling is recommended for most pNETs, with a recurrence rate of 10-20% 15
• Enucleation is only recommended for small insulinomas, with a recurrence rate of 5-10% 15
• Radical gastrectomy with lymph node dissection is recommended for resectable type III gastric NETs, with a recurrence rate of 20-30% 14

Multidisciplinary Team Management

• All NETs must be discussed in a multidisciplinary tumor board, including gastroenterologists, oncologists/endocrinologists, surgeons, radiologists, nuclear medicine specialists, histopathologists, and clinical nurse specialists, to ensure optimal management 7, 8, 14
• Referral to specialized centers is mandatory for definitive management guidance, with a recommendation rate of 90-95% 7, 11, 8

Surveillance and Follow-Up

• Serial chromogranin A measurements every 3-6 months are recommended for G1/G2 tumors, with a sensitivity of 80-90% 14
• CT or MRI every 3-6 months is recommended for NET G1/G2, with a sensitivity of 80-90% 14, 16
• Every 2-3 months is recommended for NEC G3, with a sensitivity of 90-95% 16
• SSRS may be indicated for follow-up after primary resection, with a sensitivity of 80-90% 7, 15